Cancer Research

Published by: American Association for Cancer Research  

People

  1. Traina
    Traina
  2. Hudis
    Hudis
  3. Gucalp
    Gucalp
  4. Norton
    Norton
  5. Lake
    Lake
  6. Modi
    Modi
  7. Dang
    Dang
  8. Chandarlapaty
    Chandarlapaty
  9. D'Andrea-Carlino
    D'Andrea-Carlino
  10. Feigin
    Feigin

Groups

  1. Breast Medicine Service (44)
  2. Department of Medicine (44)
  3. Solid Tumor Oncology Division (44)
  4. Survivorship Research (44)
  5. Epidemiology and Biostatistics (16)
  6. Biostatistics Service (15)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (14)
  8. GSK Faculty (9)
  9. Population Sciences Research Program (8)
  10. Radiology, Department of (7)
Search Within
  1. "Tiffany Traina"
  2. "Meeting abstract"
Formats
  1. Meeting Abstract (44)
Groups
  1. Breast Medicine Service (44)
  2. Department of Medicine (44)
  3. Solid Tumor Oncology Division (44)
  4. Survivorship Research (44)
  5. Epidemiology and Biostatistics (16)
  6. Biostatistics Service (15)

More Groups

People
  1. Tiffany Traina (44)
  2. Clifford Hudis (25)
  3. Ayca Gucalp (15)
  4. Sujata Patil (15)
  5. Larry Norton (11)
  6. Diana Lake (8)

More People

Years
  1. 2022 (1)
  2. 2021 (4)
  3. 2020 (4)
  4. 2018 (4)
  5. 2017 (2)
  6. 2016 (6)

More Years

Publishers
  1. American Association for Cancer Research (44)

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
    Meeting Abstract

    Krop, I.; Yonemori, K.; Takahashi, S.; Inoue, K.; Nakayama, T.; Iwata, H.; Toyama, T.; Yamamoto, Y.; Takahashi, M.; Osaki, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer
    Meeting Abstract

    Diéras, V.; Weaver, R.; Tolaney, S. M.; Bardia, A.; Punie, K.; Brufsky, A.; Rugo, H. S.; Kalinsky, K.; Traina, T.; Klein, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Jones, L. W.; Blinder, V.; Scott, J.; Boyle, L. A.; Arumov, A.; Alano, T.; Patil, S.; DeFusco, P.; Lamparella, N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Treatment patterns for metastatic hormone receptor-positive breast cancer: Comparing expert and community practice
    Meeting Abstract

    Quill, T.; Hurvitz, S.; Miller, K. D.; O'Regan, R.; Traina, T. A.; Andrie, R.; Obholz, K. L.; Jahanzeb, M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease
    Meeting Abstract

    Krop, I.; Masuda, N.; Kogawa, T.; Takahashi, S.; Yonemori, K.; Inoue, K.; Nakayama, T.; Yamamoto, Y.; Alvarez, R.; Toyama, T.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
    Meeting Abstract

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save

    • Cancer Research – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association Tor Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 Unknown
    Cancer research 15387445 The Authors the American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer research 15387445 American Association for Cancer Research
    Cancer Research 00085472 Unknown
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer research 15387445 Unknown
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer
    Cancer Research 00085472 The Authors
    Cancer Research 00085472 The Authors the American Association for Cancer Research